BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152-161. [PMID: 25052449 DOI: 10.1111/hepr.12393] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Herzer K, Gerken G, Hofmann TG. Hepatitis C-associated liver carcinogenesis: Role of PML nuclear bodies. World J Gastroenterol 2014; 20(35): 12367-12371 [PMID: 25253937 DOI: 10.3748/wjg.v20.i35.12367] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ikezaki H, Nomura H, Furusyo N, Ogawa E, Kajiwara E, Takahashi K, Kawano A, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C: Efficacy of beta-IFN on HCC. Hepatol Res 2016;46:E174-80. [DOI: 10.1111/hepr.12555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y; Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology. 2017;152:1383-1394. [PMID: 28163062 DOI: 10.1053/j.gastro.2017.01.041] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 12.8] [Reference Citation Analysis]
4 Abou Rached A, Saba J, Yaghi C, Sharara A, Ammar W. Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.69040] [Reference Citation Analysis]
5 Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen LB, Kharbanda KK, Osna NA, Ganesan M, Thompson KJ, Mckillop IH, Bautista A, Bataller R, French SW. Alcoholic liver disease: Clinical and translational research. Experimental and Molecular Pathology 2015;99:596-610. [DOI: 10.1016/j.yexmp.2015.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
6 Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One. 2018;13:e0209615. [PMID: 30576386 DOI: 10.1371/journal.pone.0209615] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
7 Iio E, Matsuura K, Shimada N, Atsukawa M, Itokawa N, Abe H, Kato K, Takaguchi K, Senoh T, Eguchi Y, Nomura H, Yoshizawa K, Kang JH, Matsui T, Hirashima N, Kusakabe A, Miyaki T, Fujiwara K, Matsunami K, Tsutsumi S, Iwakiri K, Tanaka Y. TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy. J Gastroenterol 2019;54:339-46. [PMID: 30382363 DOI: 10.1007/s00535-018-1526-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Kawaguchi T, Ide T, Kondo R, Nomura Y, Arinaga-Hino T, Kuwahara R, Amano K, Sano T, Akiba J, Ohshima K, Yano H, Torimura T. Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy. Exp Ther Med 2019;18:3991-4001. [PMID: 31616517 DOI: 10.3892/etm.2019.8024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 2020;50:791-816. [PMID: 32343477 DOI: 10.1111/hepr.13503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
10 Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. Cancer Med 2019;8:2646-53. [PMID: 30900818 DOI: 10.1002/cam4.2061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
11 Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y. Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. Biomedicines 2019;7:E87. [PMID: 31684167 DOI: 10.3390/biomedicines7040087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
12 Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. Intern Med 2021;60:3061-70. [PMID: 34602520 DOI: 10.2169/internalmedicine.6591-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Peyvandi F, Mahlangu JN, Pipe SW, Hay CRM, Pierce GF, Kuebler P, Kruse-Jarres R, Shima M. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost 2021;19 Suppl 1:32-41. [PMID: 33331041 DOI: 10.1111/jth.15187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 Nakamoto Y. Promising new strategies for hepatocellular carcinoma. Hepatol Res. 2017;47:251-265. [PMID: 27558453 DOI: 10.1111/hepr.12795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
15 Honda T, Ishigami M, Yamamoto K, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Kawashima H, Miyahara R, Ishikawa T, Hirooka Y, Fujishiro M. Changes in the gut microbiota after hepatitis C virus eradication. Sci Rep 2021;11:23568. [PMID: 34876650 DOI: 10.1038/s41598-021-03009-0] [Reference Citation Analysis]
16 Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Chayama K, Aikata H. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 2020;50:1222-33. [PMID: 32767446 DOI: 10.1111/hepr.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Tabu K, Mawatari S, Oda K, Taniyama O, Toyodome A, Ijuin S, Sakae H, Kumagai K, Kanmura S, Ido A. Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease. Mol Clin Oncol 2021;15:174. [PMID: 34276993 DOI: 10.3892/mco.2021.2336] [Reference Citation Analysis]
19 Nishijima N, Nasu A, Kimura T, Osaki Y. Two Cases of Hepatocellular Carcinoma Occurring Immediately after Direct-acting Antiviral Agents against Hepatitis C Virus. Intern Med 2019;58:225-31. [PMID: 30146562 DOI: 10.2169/internalmedicine.0712-17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Yuwaki K, Shimazu T, Yamagiwa Y, Inoue M, Goto A, Yamaji T, Iwasaki M, Sawada N, Tsugane S; JPHC Study Group. Association between serum liver enzymes and all-cause mortality: The Japan Public Health Center-based Prospective Study. Liver Int 2019;39:1566-76. [PMID: 30566759 DOI: 10.1111/liv.14030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kawaguchi T, Ide T, Amano K, Arinaga-Hino T, Kuwahara R, Sano T, Miki S, Ono N, Torimura T. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Mol Clin Oncol 2021;15:215. [PMID: 34476099 DOI: 10.3892/mco.2021.2377] [Reference Citation Analysis]
22 Iida H, Osaki R, Fujimoto T, Maehira H, Mori H, Kitamura N, Andoh A, Tani M. Interval between hepatocellular carcinoma treatment and interferon-free direct-acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Mol Clin Oncol 2019;11:99-105. [PMID: 31289685 DOI: 10.3892/mco.2019.1847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Tabu K, Mawatari S, Oda K, Kumagai K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Fujisaki K, Imanaka D, Kure T, Taniyama O, Toyodome A, Ijuin S, Sakae H, Sakurai K, Moriuchi A, Kanmura S, Ido A. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals. PLoS One 2020;15:e0237475. [PMID: 32790728 DOI: 10.1371/journal.pone.0237475] [Reference Citation Analysis]
24 Khan S, Khan A, Rehman AU, Ahmad I, Ullah S, Khan AA, Ali SS, Afridi SG, Wei DQ. Immunoinformatics and structural vaccinology driven prediction of multi-epitope vaccine against Mayaro virus and validation through in-silico expression. Infect Genet Evol 2019;73:390-400. [PMID: 31173935 DOI: 10.1016/j.meegid.2019.06.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
25 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49:136-146. [PMID: 30335208 DOI: 10.1111/hepr.13278] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
26 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
27 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]
28 Igarashi G, Endo T, Sawada N, Mikami K, Sato K, Kudo D, Toyoki Y, Hakamada K, Kakuta A, Shibutani K, Takai Y, Yoshizawa T, Haga T, Kijima H, Fukuda S. Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients 20 Years after Achieving a Sustained Virological Response with Interferon Therapy: A Report of Two Cases. Journal of General and Family Medicine 2015;16:199-203. [DOI: 10.14442/jgfm.16.3_199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Ochi H, Hiraoka A, Yagi S, Yukimoto A, Hirooka M, Abe M, Hiasa Y. AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. BMC Cancer 2021;21:699. [PMID: 34126947 DOI: 10.1186/s12885-021-08401-7] [Reference Citation Analysis]
30 Huang CM, Hu TH, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hung CH, Cho CL, Wu CK. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. Medicine (Baltimore) 2017;96:e8696. [PMID: 29145306 DOI: 10.1097/MD.0000000000008696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278-1287. [PMID: 29516535 DOI: 10.1111/apt.14593] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
32 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
33 Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015;121:2874-82. [PMID: 26079399 DOI: 10.1002/cncr.29528] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
34 Inukai Y, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M. The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophiliaHCC after HCV eradication in hemophilia. Ann Hepatol 2021;27:100545. [PMID: 34571264 DOI: 10.1016/j.aohep.2021.100545] [Reference Citation Analysis]
35 Asahina Y; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Hepatol Res 2020;50:775-90. [DOI: 10.1111/hepr.13501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
36 Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021;9:1491. [PMID: 34680608 DOI: 10.3390/biomedicines9101491] [Reference Citation Analysis]
37 Kuftinec G, Loehfelm T, Corwin M, Durbin-Johnson B, Candido M, Hluhanich R, Sarkar S. De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents. Hepat Oncol 2018;5:HEP06. [PMID: 30302197 DOI: 10.2217/hep-2018-0003] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Tokushima Y, Tago M, Tokushima M, Katsuki NE, Iwane S, Eguchi Y, Yamashita SI. Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study. Int J Gen Med 2020;13:743-50. [PMID: 33061544 DOI: 10.2147/IJGM.S268857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Ishida H, Takemura M, Suetsugu A, Naiki T, Tanaka T, Eiichi T, Serrero G, Matsunami H, Yamamoto Y, Saito K. Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents. Ann Clin Biochem 2021;:45632211036723. [PMID: 34284614 DOI: 10.1177/00045632211036723] [Reference Citation Analysis]
40 Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miuma S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, Torimura T. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int. 2019;13:293-301. [PMID: 30820753 DOI: 10.1007/s12072-019-09939-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
41 Aly OA, Yousry WA, Teama NM, Shona EM, Elghandour AM. Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00056-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int 2017;16:470-9. [PMID: 28992878 DOI: 10.1016/S1499-3872(17)60044-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
43 Krastev Z, Jelev D, Antonov K, Petkova T, Atanasova E, Zheleva N, Tomov B, Boyanova Y, Mateva L. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. World J Gastroenterol 2016; 22(8): 2630-2635 [PMID: 26937151 DOI: 10.3748/wjg.v22.i8.2630] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
44 Matsuura K, Tanaka Y. Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatol Res 2018;48:127-33. [PMID: 29235266 DOI: 10.1111/hepr.13042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
45 Kawaguchi T, Ide T, Koga H, Kondo R, Miyajima I, Arinaga-Hino T, Kuwahara R, Amano K, Niizeki T, Nakano M, Kuromatsu R, Torimura T. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol 2018;11:69-74. [PMID: 29082453 DOI: 10.1007/s12328-017-0789-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
46 Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H. Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. Hepatol Res 2018;48:E78-86. [PMID: 28643404 DOI: 10.1111/hepr.12929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
47 Weil C, Mehta D, Koren G, Pinsky B, Samp JC, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. J Viral Hepat 2018;25:144-51. [PMID: 28984012 DOI: 10.1111/jvh.12800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
48 Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, Koga H, Torimura T. Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers 2022;14:2295. [DOI: 10.3390/cancers14092295] [Reference Citation Analysis]